Central and Peripheral Inflammation in Mild Cognitive Impairment in the Context of Alzheimer’s Disease
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms241310523 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Inès Schmidt-Morgenroth und 3 weiteren Autor:innen. Beteiligte Einrichtung: Novartis Institutes for Biomedical Research (NIBR), Translational Medicine, 4056 Basel, Switzerland. Hauptthemen laut MEDLINE: Alzheimer Disease, Neurodegenerative Diseases, Cognitive Dysfunction. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Demenz
Abstract (Originalsprache)
Mild cognitive impairment (MCI) is characterized by an abnormal decline in mental and cognitive function compared with normal cognitive aging. It is an underlying condition of Alzheimer’s disease (AD), an irreversible neurodegenerative disease. In recent years, neuroinflammation has been investigated as a new leading target that contributes to MCI progression into AD. Understanding the mechanism underlying inflammatory processes involved in the early onset of the disease could help find a safe and effective way to diagnose and treat patients. In this article, we assessed over twenty different blood and cerebrospinal fluid (CSF) inflammatory biomarker concentrations with immunoassay methods in patients with MCI (mild cognitive impairment), non-impaired control (NIC), and serum healthy control (HC). We performed group comparisons and analyzed in-group correlations between the biomarkers. We included 107 participants (mean age: 64.7 ± 7.8, women: 58.9%). CSF osteopontin and YKL-40 were significantly increased in the MCI group, whereas serum C-reactive protein and interleukin-6 were significantly higher (p < 0.001) in the NIC group compared with the MCI and HC groups. Stronger correlations between interleukin-1β and inflammasome markers were observed in the serum of the MCI group. We confirmed specific inflammatory activation in the central nervous system and interleukin-1β pathway upregulation in the serum of the MCI cohort.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Novartis Institutes for Biomedical Research (NIBR), Translational Medicine, 4056 Basel, Switzerland.
- Institut Pascal, Université Clermont Auvergne, CNRS, Clermont Auvergne INP, 63000 Clermont-Ferrand, France.
ORCID-Profile: Philippe Michaud
Zitieren
APA
Schmidt-Morgenroth, I., Michaud, P., Gasparini, F., & Avrameas, A. (2023). Central and Peripheral Inflammation in Mild Cognitive Impairment in the Context of Alzheimer’s Disease. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241310523
Vancouver
Schmidt-Morgenroth I, Michaud P, Gasparini F, Avrameas A. Central and Peripheral Inflammation in Mild Cognitive Impairment in the Context of Alzheimer’s Disease. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241310523
BibTeX
@article{SchmidtMorgenroth2023,
author = {Schmidt-Morgenroth, Inès and Michaud, Philippe and Gasparini, Fabrizio and Avrameas, Alexandre},
title = {Central and Peripheral Inflammation in Mild Cognitive Impairment in the Context of Alzheimer’s Disease},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms241310523}
}
EUVIMED